| 产品描述： | K 01-162 (K162) inhibits the fibril formation of Aβ peptides and eliminates their neurotoxicity. K 01-162 binds with Aβ42 peptide with an EC50 value of 80 nM. K 01-162 binds directly to AβO with a KD value of 19 μM. K 01-162 is capable of penetrating the brain and can be used for the research of Alzheimer’s disease |
| 靶点： |
Amyloid-β |
| 体外研究： |
K 01-162 (1 μM; 24 h) reduces the level of intracellular AβO. K 01-162 (0.78-50 μM; 5 min) blocks the synaptic binding activity of AβO in mouse hippocampal neurons. Western Blot Analysis Cell Line: MC65 cell line Concentration: 1 μM Incubation Time: 24 hours Result: Reduced the levels of SDS-stable Aβ trimer and larger aggregates. |
| 体内研究： |
K 01-162 (100 μM; intracerebroventricular infusion 0.25 μL/h for 2 weeks) attenuates amyloid load in vivo. Animal Model: 5xFAD mice with cerebral Aβ amyloidosis Dosage: 100 μM Administration: Intracerebroventricular infusion; 100 μM 0.25 μL/h; for 2 weeks Result: Caused no apparent toxicity and significantly reduced the amyloid load in hippocampus to 50% of the mock-treated |
| 参考文献： |
1. Li J, et al. Alzheimer's disease drug candidates stabilize A-β protein native structure by interacting with the hydrophobic core. Biophys J. 2011 Feb 16;100(4):1076-82. 2. Hong HS, et al. Candidate anti-A beta fluorene compounds selected from analogs of amyloid imaging agents. Neurobiol Aging. 2010 Oct;31(10):1690-9. |
| 溶解性： |
Soluble in DMSO |
| 保存条件： |
-20℃ |
| 配置溶液浓度参考： |
|
1mg |
5mg |
10mg |
| 1 mM |
3.47 ml |
17.35 ml |
34.7 ml |
| 5 mM |
0.694 ml |
3.47 ml |
6.94 ml |
| 10 mM |
0.347 ml |
1.735 ml |
3.47 ml |
| 50 mM |
0.069 ml |
0.347 ml |
0.694 ml |
|
| 注意： |
部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京